Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.65 |
| ▸ | CTSL | P07711 | 5/20 | 0.65 |
| ▸ | CTSS | P25774 | 2/20 | 0.65 |
| ▸ | CTSK | P43235 | 2/20 | 0.65 |
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119250 | 1.00 | PSMB5 (0.65) | PSMB5CTSLCTSSCTSKLTA4H | |
| SCHEMBL7315389 | 0.95 | PSMB5 (0.60) | PSMB5CTSLCTSSCTSKLTA4H | |
| SCHEMBL10119263 | 0.93 | CTSS (0.60) | PSMB5CTSLCTSSCTSKMME | |
| SCHEMBL10118946 | 0.93 | CTSS (0.67) | PSMB5CTSLCTSSCTSKMME | |
| SCHEMBL14297648 | 0.93 | CTSS (0.60) | PSMB5CTSLCTSSCTSKMME | |
| SCHEMBL7315385 | 0.92 | PSMB5 (0.58) | PSMB5CTSLCTSSCTSKLTA4H | |
| SCHEMBL7327671 | 0.92 | PSMB5 (0.58) | PSMB5CTSLCTSSCTSKLTA4H | |
| SCHEMBL10119270 | 0.91 | PSMB5 (0.56) | PSMB5CTSLCTSSCTSKCTSB | |
| SCHEMBL12516880 | 0.91 | PSMB5 (0.56) | PSMB5CTSLCTSSCTSKLTA4H | |
| SCHEMBL10118961 | 0.91 | USP30 (0.56) | PSMB5CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8637453-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2012004554-A1 | ALDEHYDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011089396-A2 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE. | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2011-07-28 | — | — | WO | disclosed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5158936-A | Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | PSMB5 484/4885CTSL 535/4885CTSS 288/4885 |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, PEPD | PSMB5 408/4885CTSL 669/4885CTSS 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.